Updates are available Correction dated 2025-06-28
Click to view Correction: https://doi.org/10.1007/s12094-025-03941-x
-
Authors
Alsina Maqueda, Maria https://orcid.org/0000-0003-4835-7159
Teijo Quintáns, Ana https://orcid.org/0000-0002-8280-8446
Cuatrecasas, Miriam https://orcid.org/0000-0003-3063-0110
Fernández Aceñero, Maria Jesús https://orcid.org/0000-0002-2439-3553
Fernández Montes, Ana https://orcid.org/0000-0003-4630-5830
Gómez Martín, Carlos https://orcid.org/0000-0002-1929-0955
Jiménez Fonseca, Paula https://orcid.org/0000-0003-4592-3813
Martínez Ciarpaglini, Carolina https://orcid.org/0000-0002-8797-2114
Rivera Herrero, Fernando https://orcid.org/0000-0001-8915-226X
Iglesias Coma, Mar https://orcid.org/0000-0002-2274-4671
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica
- License Information
-
More Information
Article History
Received: 24 January 2025
Accepted: 28 January 2025
First Online: 12 March 2025
Change Date: 29 June 2025
Change Type: Update
Change Details: The original online version of this article was revised to correct the errors in the text and references section.
Change Date: 28 June 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12094-025-03941-x
Declarations
:
: AMM has participated in consulting and/or advisory boards for Amgen, AstraZeneca, BeiGene, Jazz Pharmaceuticals, BMS, Novartis and MSD. Speaker honoraria from Astellas, Beigene, Jazz Pharmaceuticals. ICM has participated in consulting and/or advisory boards for BeiGene, BMS, Astellas, Roche, Gilead, AstraZeneca, and MSD. Speaker honoraria from Astellas, BMS, MSD, Merck, Daichii-Sankyo, Servier and Roche. TQA has participated in consulting and/or advisory boards of GSK, MSD and Roche. CMC has participated in consulting and/or advisory boards for BeiGene, BMS, Astellas, Gilead, and MSD. Speaker honoraria from Astellas, BMS, MSD, and Roche. JFP received honoraria for speakers' bureau participation, and serving on advisory boards from Astellas, AstraZeneca, Bristol-Myers Squibb (BMS), Esteve, Merck Sharp & Dohme (MSD), Novartis, Nutricia, Pfizer, Rovi, Takeda, and Viatris and research grants from Astellas, AstraZeneca, BMS, and MSD. RHF Consultant or Advisory Role: Roche, Merck-Serono, Amgen, MSD, BMS, Lilly, Celgene, Sanofi-Aventis, Servier, Astra-Zeneca, Bayer, Astellas, Organon. Research Funding: Roche, Merck-Serono, Amgen, MSD, Lilly, Celgene, Sanofi-Aventis, Servier, Bayer. Speaking: Roche, Merck-Serono, Amgen, MSD, BMS, Lilly, Celgene, Sanofi-Aventis, Servier, Bayer. Grant support: Amgen, MSD, BMS.
: Not applicable.
: Not applicable.
: Not applicable.
